Plain-English translation of NCT07239596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called SHR-8068, combined with another drug called Adebrelimab and additional cancer treatments, to see if together they can help people with advanced kidney cancer. Researchers want to find out if this combination is safe and how well it works at slowing or stopping the cancer's growth. The trial will enroll about 139 people and test different combinations of these medications.
Advanced kidney cancer is difficult to treat, especially when it cannot be surgically removed or has spread to other parts of the body. Doctors are looking for new drug combinations that might work better than existing treatments while being manageable for patients to tolerate.
You likely qualify if…
You likely don't qualify if…
If you are accepted into the study, you will receive the medication combination through regular clinic visits. You will be assigned to one of three treatment groups, each testing a slightly different combination of medications. During the trial, you will have blood tests, imaging scans, and physical exams to monitor how you are responding and to watch for any side effects. The study will continue as long as the treatment is helping you and you are tolerating it well.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China